109 related articles for article (PubMed ID: 25398756)
1. Successful integration of nonclinical and clinical findings in interpreting the clinical relevance of rodent neoplasia with a new chemical entity.
Ways K; Johnson MD; Mamidi RN; Proctor J; De Jonghe S; Louden C
Toxicol Pathol; 2015 Jan; 43(1):48-56. PubMed ID: 25398756
[TBL] [Abstract][Full Text] [Related]
2. Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin.
De Jonghe S; Proctor J; Vinken P; Feyen B; Wynant I; Marien D; Geys H; Mamidi RN; Johnson MD
Chem Biol Interact; 2014 Dec; 224():1-12. PubMed ID: 25289773
[TBL] [Abstract][Full Text] [Related]
3. Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin.
Mamidi RN; Proctor J; De Jonghe S; Feyen B; Moesen E; Vinken P; Ma JY; Bryant S; Snook S; Louden C; Lammens G; Ways K; Kelley MF; Johnson MD
Chem Biol Interact; 2014 Sep; 221():109-18. PubMed ID: 25130857
[TBL] [Abstract][Full Text] [Related]
4. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Brunton S; Reid TS
Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
[TBL] [Abstract][Full Text] [Related]
5. Renal tubular and adrenal medullary tumors in the 2-year rat study with canagliflozin confirmed to be secondary to carbohydrate (glucose) malabsorption in the 15-month mechanistic rat study.
De Jonghe S; Johnson MD; Mamidi RNVS; Vinken P; Feyen B; Lammens G; Proctor J
Chem Biol Interact; 2017 Nov; 277():85-90. PubMed ID: 28916336
[TBL] [Abstract][Full Text] [Related]
6. Canagliflozin use in patients with renal impairment-Utility of quantitative clinical pharmacology analyses in dose optimization.
Khurana M; Vaidyanathan J; Marathe A; Mehrotra N; Sahajwalla CG; Zineh I; Jain L
J Clin Pharmacol; 2015 Jun; 55(6):647-56. PubMed ID: 25612234
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Nyirjesy P; Zhao Y; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1173-8. PubMed ID: 22632452
[TBL] [Abstract][Full Text] [Related]
8. Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin.
Bogdanffy MS; Stachlewitz RF; van Tongeren S; Knight B; Sharp DE; Ku W; Hart SE; Blanchard K
Int J Toxicol; 2014; 33(6):436-49. PubMed ID: 25260362
[TBL] [Abstract][Full Text] [Related]
9. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Nicolle LE; Capuano G; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
[TBL] [Abstract][Full Text] [Related]
11. A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes.
Boyle LD; Wilding JP
Expert Opin Drug Saf; 2014 Nov; 13(11):1535-44. PubMed ID: 25340618
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
Devineni D; Curtin CR; Polidori D; Gutierrez MJ; Murphy J; Rusch S; Rothenberg PL
J Clin Pharmacol; 2013 Jun; 53(6):601-10. PubMed ID: 23670707
[TBL] [Abstract][Full Text] [Related]
13. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
[TBL] [Abstract][Full Text] [Related]
14. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M
J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635
[TBL] [Abstract][Full Text] [Related]
15. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.
Sha S; Devineni D; Ghosh A; Polidori D; Chien S; Wexler D; Shalayda K; Demarest K; Rothenberg P
Diabetes Obes Metab; 2011 Jul; 13(7):669-72. PubMed ID: 21457428
[TBL] [Abstract][Full Text] [Related]
16. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
Stein P; Berg JK; Morrow L; Polidori D; Artis E; Rusch S; Vaccaro N; Devineni D
Metabolism; 2014 Oct; 63(10):1296-303. PubMed ID: 25110280
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacological and clinical profile of a novel SGLT2 inhibitor canagliflozin hydrate (CANAGLU®)].
Kuriyama C; Ueta K; Arakawa K
Nihon Yakurigaku Zasshi; 2015 Dec; 146(6):332-41. PubMed ID: 26657125
[No Abstract] [Full Text] [Related]
18. Empagliflozin for the treatment of Type 2 diabetes.
Gangadharan Komala M; Mather A
Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
[TBL] [Abstract][Full Text] [Related]
19. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
20. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
Neal B; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Stein P; Desai M; Shaw W; Jiang J; Vercruysse F; Meininger G; Matthews D
Am Heart J; 2013 Aug; 166(2):217-223.e11. PubMed ID: 23895803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
